Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Birner, A; Bengesser, SA; Seiler, S; Dalkner, N; Queissner, R; Platzer, M; Fellendorf, FT; Hamm, C; Maget, A; Pilz, R; Lenger, M; Reininghaus, B; Pirpamer, L; Ropele, S; Hinteregger, N; Magyar, M; Deutschmann, H; Enzinger, C; Kapfhammer, HP; Reininghaus, EZ.
Total gray matter volume is reduced in individuals with bipolar disorder currently treated with atypical antipsychotics.
J Affect Disord. 2020; 260(9):722-727 Doi: 10.1016/j.jad.2019.09.068
Web of Science PubMed FullText FullText_MUG

 

Leading authors Med Uni Graz
Bengesser Susanne
Birner Armin
Co-authors Med Uni Graz
Dalkner Nina
Deutschmann Hannes
Enzinger Christian
Fellendorf Frederike
Hamm Carlo
Hinteregger Nicole
Kapfhammer Hans-Peter
Lenger Melanie
Maget Alexander
Magyar Marton
Pilz Rene
Pirpamer Lukas
Platzer Martina
Queissner Robert
Reininghaus Bernd
Reininghaus Eva
Ropele Stefan
Seiler Stephan
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Recent evidence indicates that the intake of atypical antipsychotics (AAP) is associated with gray matter abnormalities in patients with psychiatric disorders. We explored if patients with bipolar disorder (BD) who are medicated with AAP exhibit total gray matter volume (TGV) reduction compared to BD individuals not medicated with AAP and healthy controls (HC). In a cross-sectional design, 124 individuals with BD and 86 HC underwent 3T-MRI of the brain and clinical assessment as part of our BIPFAT-study. The TGV was estimated using Freesurfer. We used univariate covariance analysis (ANCOVA) to test for normalized TGV differences and controlled for covariates. ANCOVA results indicated that 75 BD individuals taking AAP had significantly reduced normalized TGV as compared to 49 BD not taking AAP (F = 9.995, p = .002., Eta = 0.084) and 86 HC (F = 7.577, p = .007, Eta = 0.046). Our cross-sectional results are not suited to draw conclusions about causality. We have no clear information on treatment time and baseline volumes before drug treatment in the studied subjects. We cannot exclude that patients received different psychopharmacologic medications prior to the study point. We did not included dosages into the calculation. Many BD individuals received combinations of psychopharmacotherapy across drug classes. We did not have records displaying quantitative alcohol consumption and drug abuse in our sample. Our data provide further evidence for the impact of AAP on brain structure in BD. Longitudinal studies are needed to investigate the causal directions of the proposed relationships. Copyright © 2019. Published by Elsevier B.V.

Find related publications in this database (Keywords)
Bipolar disorder
Gray matter volume
Magnetic resonance imaging
Psychopharmacology
Antipsychotics
© Med Uni GrazImprint